Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Pollyea

Showing results (71-80 of 179) with videos related to

Pageof 18
Sort By:
Leukemia & Lymphoma|May 30, 2024
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemiaJacob Fang, Grace Bosma, Dara Aisner, et al.
Leukemia & Lymphoma|June 12, 2012
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levelsDaniel A Pollyea, Holbrook E Kohrt, Bing Zhang, et al.
Blood Advances|May 23, 2020
Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplantPrashant Sharma, Enkhtsetseg Purev, Bradley Haverkos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid LeukemiaDaniel A Pollyea, John Barrett, Courtney D DiNardo, et al.
Haematologica|November 4, 2017
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemiaBruno C Medeiros, Kelly McCaul, Suman Kambhampati, et al.
Haematologica|March 9, 2019
Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signalingDaniel A Pollyea, Chelsea Harris, Jennifer L Rabe, et al.
Haematologica|March 11, 2017
Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1Maura Gasparetto, Shanshan Pei, Mohammad Minhajuddin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 22, 2006
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantationAndrew S Artz, Daniel A Pollyea, Masha Kocherginsky, et al.
Haematologica|December 18, 2012
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemiaDaniel A Pollyea, James Zehnder, Steve Coutre, et al.
European Journal of Haematology|May 31, 2023
Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemiaJonathan Canaani, Avraham Frisch, Daniel A Pollyea, et al.
Pageof 18

Showing results (71-80 of 179) with videos related to

Sort By:
Pageof 18
Leukemia & Lymphoma|May 30, 2024
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemiaJacob Fang, Grace Bosma, Dara Aisner, et al.
Leukemia & Lymphoma|June 12, 2012
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levelsDaniel A Pollyea, Holbrook E Kohrt, Bing Zhang, et al.
Blood Advances|May 23, 2020
Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplantPrashant Sharma, Enkhtsetseg Purev, Bradley Haverkos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid LeukemiaDaniel A Pollyea, John Barrett, Courtney D DiNardo, et al.
Haematologica|November 4, 2017
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemiaBruno C Medeiros, Kelly McCaul, Suman Kambhampati, et al.
Haematologica|March 9, 2019
Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signalingDaniel A Pollyea, Chelsea Harris, Jennifer L Rabe, et al.
Haematologica|March 11, 2017
Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1Maura Gasparetto, Shanshan Pei, Mohammad Minhajuddin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 22, 2006
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantationAndrew S Artz, Daniel A Pollyea, Masha Kocherginsky, et al.
Haematologica|December 18, 2012
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemiaDaniel A Pollyea, James Zehnder, Steve Coutre, et al.
European Journal of Haematology|May 31, 2023
Venetoclax-based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemiaJonathan Canaani, Avraham Frisch, Daniel A Pollyea, et al.
Pageof 18